Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04735757
Other study ID # NL 72271.029.19
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 3, 2021
Est. completion date January 19, 2023

Study information

Verified date March 2021
Source VU University Medical Center
Contact Leo Heunks, Prof. Dr.
Phone (020) 444 4444
Email l.heunks@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

COVID-19-infection has a large impact on the respiratory system and possibly on the diaphragm, the main respiratory muscle. In ICU-patients, diaphragm weakness is associated with prolonged ICU-stay, difficult weaning and increased mortality. Our research group recently found evidence for fibrosis and expression of genes involved in fibrosis as well as viral infiltration of the SARS-CoV-2 virus in diaphragm biopsies from COVID-19 ICU patients. This finding suggests a unique manifestation of diaphragm injury in COVID-19 patients after mechanical ventilation. However, it remains unclear what the exact nature and location of diaphragm injury is. Additionally, it is largely unknown whether this injury affects the movement of the diaphragm, but this might have important clinical implications. Therefore, we aim at visualizing the tissue characteristics and movement of the diaphragm in COVID-19 patients who recently received long-term mechanical ventilation, other ICU patients and healthy controls, using magnetic resonance imaging (MRI). MRI of the diaphragm was already shown feasible in previous research from our group (article currently under review). New insights in the characteristics of diaphragm weakness and injury in COVID-19 patients and control ICU-patients will contribute to strategies to prevent it and monitor the diaphragm of patients under mechanical ventilation, which can contribute to better patient outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date January 19, 2023
Est. primary completion date January 19, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria In order to be eligible to participate in this study, a subject in the case group must meet all of the following criteria: - Invasive mechanical ventilation > 72 hours during current hospital admission - Admitted for COVID-19-infection (n = 10) - Currently negative COVID-19 PCR test - Discharged from the ICU = 7 days ago - Signed informed consent - Age = 18 years In order to be eligible to participate in this study, a subject in the control group must meet all of the following criteria: - Signed informed consent - Age = 18 years - Similar age (max 5 years difference) and gender of one of the subjects in case group Exclusion criteria A potential subject for the case group who meets any of the following criteria will be excluded from participation in this study: - Known history of: - Diaphragmatic injury or weakness prior to ICU stay - COPD (GOLD IV) - Neuromuscular disease (including pathology of the n. phrenicus) - Connective tissue disease - Chronic use of corticosteroids (>7.5 mg/day for at least 3 months before hospital admission) - >10% weight loss within last 6 months prior to ICU admission - Obesity (BMI > 30 kg/m2 at hospital admission) - Known pregnancy - Contraindications for MRI - Electrical/metallic implants - Claustrophobia - Unable to hold breath for 10 seconds - Hierarchical relation with one of the collaborating investigators - Incapacitation - Contraindications for the use of a Gadolinium based contrast agent for MRI - Known eGFR < 30 ml/min/1.73m2 - Known history of allergic reactions to an MRI contrast medium - Known history of allergic reactions requiring immediate treatment - Known history of atopy - Asthma These exclusion criteria are based on the guidelines for contrast agents from the European Society for Urogenital Radiology (http://www.esur.org/guidelines/). Additional exclusion criteria for the case group, subset non-infected patients are: • History of COVID-19-infection (confirmed with positive test) Additional exclusion criteria for the control group are: - History of mechanical ventilation > 24 hours - History of COVID-19-infection (confirmed with positive test)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Contrast-enhanced MRI
Contrast-enhanced MRI
Measurement of respiratory muscle force
Measurement of the maximum inspiratory and expiratory pressure.

Locations

Country Name City State
Netherlands Amsterdam UMC, location VUmc Amsterdam Noord-Holland

Sponsors (1)

Lead Sponsor Collaborator
VU University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation of diaphragm tissue characteristics with tissue characteristics of the abdominal muscles 1 hour
Primary Tissue characteristics of the diaphragm Extracted from contrast enhanced imaging 1 hour
Primary Movement of the diaphragm Description of the movement of the diaphragm in 4D fashion. 1 hour
Secondary Quantitative dynamic contrast enhanced imaging of the diaphragm Application of modelling to describe tissue characteristics of the diaphragm using contrast inflow. 1 hour
Secondary Correlation of movement and tissue characteristics of the diaphragm with measurements of maximum inspiratory and expiratory pressure 1 hour
Secondary Correlation of movement and tissue characteristics of the diaphragm with clinical parameters Clinical parameters include ventilator settings, biomarkers for inflammation (CRP, white blood cell count) during ICU admission, daily dosage of drugs known with adverse effects on respiratory muscles, fluid balance, protein intake, primary reason for ICU admission and weaning duration. 1 hour
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3